Genmab — Oktober 2020
-
-
Aktier/tendens: Nordea løber med opmærksomheden i ventet grøn starthttps://www.proinvestor.com/investornyt/668910/aktier-tendens-nordea-lober-med-opmaerksomheden-i-ventet-gron-start
-
Egentlig ikke en nyhed, men faldt over denne: Daratumumab potentiates the antitumor activity of CHOP and R-CHOP in MCL and FL xenografts. Furthermore, in a patient-derived DLBCL xenograft model, daratumumab anti-tumor activity was comparable to R-CHOP and the addition of daratumumab to either CHOP or R-CHOP led to full tumor regression.
-
our findings warrant further clinical development of daratumumab in NHL providing a strong rationale for examining its clinical efficacy in different scenarios, including maintenance therapy after induction therapy, cases with anti-CD20 resistance, FL histologic transformation, and as frontline in combination with the standard of care (CHOP/ R-CHOP)
-
Tusinde tak for info GTG.
-
Nåja, sà skal dara konkurrere med epco
-
Selvfølgelig
-
)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind